Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 44

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

mTOR-dependent dysregulation of autophagy contributes to the retinal ganglion cell loss in streptozotocin-induced diabetic retinopathy

Madrakhimov, Sanjar Batirovich, Yang, Jin Young, Kim, Jin Ha, Han, Jung Woo, Park, Tae Kwann · 2021 · Cell Communication and Signaling

Published version of a preprint

Abstract

Background: Neurodegeneration, an early event in the pathogenesis of diabetic retinopathy (DR), precedes clinically detectable microvascular damage. Autophagy dysregulation is considered a potential cause of neuronal cell loss, however underlying mechanisms remain unclear. The mechanistic target of rapamycin (mTOR) integrates diverse environmental signals to coordinate biological processes, including autophagy. Here, we investigated the role of mTOR signaling in neuronal cell death in DR. Methods: Diabetes was induced by a single intraperitoneal injection of streptozotocin and tissue samples were harvested at 1, 2, 3, 4, and 6 months of diabetes. Early-stage of DR was investigated in 1-month-diabetic mice treated with phlorizin (two daily subcutaneous injections at a dose of 200 mg/kg of body weight during the last 7 full days of the experiment and the morning of the 8th day, 3 h before sacrifice) or rapamycin (daily intraperitoneal injections, at a dose of 3 mg/kg for the same period as for phlorizin treatment). The effect of autophagy modulation on retinal ganglion cells was investigated in 3-months-diabetic mice treated with phlorizin (two daily subcutaneous injections during the last 10 full days of the experiment and the morning of the 11th day, 3 h before sacrifice) or MHY1485 (daily i.p. injections, at a dose of 10 mg/kg for the same period as for phlorizin treatment). Tissue samples obtained from treated/untreated diabetic mice and age-matched controls were used for Western blot and histologic analysis. Results: mTOR-related proteins and glucose transporter 1 (GLUT1) was upregulated at 1 month and downregulated in the following period up to 6 months. Diabetes-induced neurodegeneration was characterized by an increase of apoptotic marker—cleaved caspase 3, a decrease of the total number of cells, and NeuN immunoreactivity in the ganglion cell layer, as well as an increase of autophagic protein. Insulin-independent glycemic control restored the mTOR pathway activity and GLUT1 expression, along with a decrease of autophagic and apoptotic proteins in 3-months-diabetic mice neuroretina. However, blockade of autophagy using MHY1485 resulted in a more protective effect on ganglion cells compared with phlorizin treatment. Conclusion: Collectively, our study describes the mechanisms of neurodegeneration through the hyperglycemia/ mTOR/ autophagy/ apoptosis pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12964-020-00698-4

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 72

  1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36. https://doi.org/10.1016/S0140-6736(09)62124-3. · DOI · Paper page
  2. Gadkari SS, Maskati QB, Nayak BK. Prevalence of diabetic retinopathy in India: The All India Ophthalmological Society Diabetic Retinopathy Eye Screening Study 2014. Indian J Ophthalmol. 2016;64(1):38–44. https://doi.org/10.4103/0301-4738.178144. · DOI · Paper page
  3. Thomas RL, Dunstan FD, Luzio SD, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol. 2015;99(1):64–8. https://doi.org/10.1136/bjophthalmol-2013-304017. · DOI · Paper page
  4. Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260–77. https://doi.org/10.1111/ceo.12696. · DOI · Paper page
  5. Bandello F, Lattanzio R, Zucchiatti I, Del Turco C. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013;50(1):1–20. https://doi.org/10.1007/s00592-012-0449-3. · DOI
  6. Wu L, Fernandez-Loaiza P, Sauma J, Hernandez-Bogantes E, Masis M. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4(6):290. https://doi.org/10.4239/wjd.v4.i6.290. · DOI · Paper page
  7. Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–86. https://doi.org/10.1016/j.preteyeres.2015.08.001. · DOI · Paper page
  8. Cole ED, Novais EA, Louzada RN, Waheed NK. Contemporary retinal imaging techniques in diabetic retinopathy: a review. Clin Exp Ophthalmol. 2016;44(4):289–99. https://doi.org/10.1111/ceo.12711. · DOI · Paper page
  9. Tavares Ferreira J, Alves M, Dias-Santos A, et al. Retinal neurodegeneration in diabetic patients without diabetic retinopathy. Investig Ophthalmol Vis Sci. 2016;57(14):6455–60. https://doi.org/10.1167/iovs.16-20215. · DOI
  10. Jackson GR, Barber AJ. Visual dysfunction associated with diabetic retinopathy. Curr Diab Rep. 2010;10(5):380–4. https://doi.org/10.1007/s11892-010-0132-4. · DOI
  11. Han Y, Adams AJ, Bearse MA, Schneck ME. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol. 2004;122(12):1809–15. https://doi.org/10.1001/archopht.122.12.1809. · DOI
  12. Harrison WW, Bearse MA, Ng JS, et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Investig Ophthalmol Vis Sci. 2011;52(2):772–7. https://doi.org/10.1167/iovs.10-5931. · DOI · Paper page
  13. Lecleire-Collet A, Audo I, Aout M, et al. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Investig Ophthalmol Vis Sci. 2011;52(6):2861–7. https://doi.org/10.1167/iovs.10-5960. · doi:10.1167/iovs.10-5960
  14. Verma A, Raman R, Vaitheeswaran K, et al. Does neuronal damage precede vascular damage in subjects with type 2 diabetes mellitus and having no clinical diabetic retinopathy? Ophthalmic Res. 2012;47(4):202–7. https://doi.org/10.1159/000333220. · DOI
  15. Vujosevic S, Midena E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and müller cells alterations. J Diabetes Res. 2013;2013:905058. https://doi.org/10.1155/2013/905058. · DOI · Paper page
  16. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest. 1998;102(4):783–91. https://doi.org/10.1172/JCI2425. · DOI · Paper page
  17. Carrasco E, Hernandez C, Miralles A, et al. Lower somatostatin expression is an early event in diabetic retinopathy and is. Diabetes Care. 2007;30(11):2902–8. https://doi.org/10.2337/dc07-0332.Additional. · doi:10.2337/dc07-0332.additional
  18. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Investig Ophthalmol Vis Sci. 2007;48(11):5152–9. https://doi.org/10.1167/iovs.07-0427. · DOI
  19. Aung MH, Park H, Han MK, et al. Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes. J Neurosci. 2014;34(3):726–36. https://doi.org/10.1523/JNEUROSCI.3483-13.2014. · DOI
  20. Gastinger MJ, Singh RSJ, Barber AJ. Loss of Cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Investig Opthalmology Vis Sci. 2006;47(7):3143. https://doi.org/10.1167/iovs.05-1376. · DOI · Paper page
  21. Rungger-Brändle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Investig Ophthalmol Vis Sci. 2000;41(7):1971–80.
  22. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17(3):463–71. https://doi.org/10.1017/S0952523800173122. · DOI · Paper page
  23. Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia. 2010;53(5):971–9. https://doi.org/10.1007/s00125-009-1655-6. · DOI · Paper page
  24. Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci. 2014;1311:174–90. https://doi.org/10.1111/nyas.12412. · DOI · Paper page
  25. Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160–80. https://doi.org/10.1016/j.preteyeres.2015.04.003. · DOI · Paper page
  26. Simó R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia. 2018;61(9):1902–12. https://doi.org/10.1007/s00125-018-4692-1. · DOI · Paper page
  27. Gardner TW, Davila JR. The neurovascular unit and the pathophysiologic basis of diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2017;255(1):1–6. https://doi.org/10.1007/s00417-016-3548-y. · DOI · Paper page
  28. Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55(9):2401–11. https://doi.org/10.2337/db05-1635. · DOI · Paper page
  29. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Investig Ophthalmol Vis Sci. 2011;52(2):1156–63. https://doi.org/10.1167/iovs.10-6293. · DOI · Paper page
  30. Simó R, Hernández C. Neurodegeneration is an early event in diabetic retinopathy: Therapeutic implications. Br J Ophthalmol. 2012;96(10):1285–90. https://doi.org/10.1136/bjophthalmol-2012-302005. · DOI
  31. Piano I, Novelli E, Della Santina L, Strettoi E, Cervetto L, Gargini C. Involvement of autophagic pathway in the progression of retinal degeneration in a mouse model of diabetes. Front Cell Neurosci. 2016;10(FEB):42. https://doi.org/10.3389/fncel.2016.00042. · DOI
  32. Park H-YL, Kim JH, Park CK. Different contributions of autophagy to retinal ganglion cell death in the diabetic and glaucomatous retinas. Sci Rep. 2018;8(1):13321. https://doi.org/10.1038/s41598-018-30165-7. · DOI
  33. De Faria JMLJBL, Duarte DA, Montemurro C, et al. Defective autophagy in diabetic retinopathy. Investig Ophthalmol Vis Sci. 2016;57(10):4356–66. https://doi.org/10.1167/iovs.16-19197. · DOI
  34. Lin WJ, Kuang HY. Oxidative stress induces autophagy in response to multiple noxious stimuli in retinal ganglion cells. Autophagy. 2014;10(10):1692–701. https://doi.org/10.4161/auto.36076. · DOI
  35. Di RM, Distefano G, Gagliano C, Rusciano D, Malaguarnera L. Autophagy in diabetic retinopathy. Curr Neuropharmacol. 2016;14(8):810–25. https://doi.org/10.2174/1570159X14666160321122900. · DOI
  36. Saha S, Panigrahi DP, Patil S, Bhutia SK. Autophagy in health and disease: a comprehensive review. Biomed Pharmacother. 2018;104:485–95. https://doi.org/10.1016/j.biopha.2018.05.007. · DOI · Paper page
  37. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–8. https://doi.org/10.1002/dmrr.532. · DOI · Paper page
  38. Fort PE, Losiewicz MK, Reiter CEN, et al. Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance. PLoS ONE. 2011. https://doi.org/10.1371/journal.pone.0026498. · DOI
  39. Sällström J, Eriksson T, Fredholm BB, Persson AEG, Palm F. Inhibition of sodium-linked glucose reabsorption normalizes diabetes-induced glomerular hyperfiltration in conscious adenosine A1-receptor deficient mice. Acta Physiol. 2014;210(2):440–5. https://doi.org/10.1111/apha.12152. · DOI
  40. Yang JY, Madrakhimov SB, Ahn DH, et al. mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV. Cell Commun Signal. 2019;17(1):64. https://doi.org/10.1186/s12964-019-0380-0. · DOI
  41. Zhou J, Yao W, Li C, Wu W, Li Q, Liu H. Administration of follicle-stimulating hormone induces autophagy via upregulation of HIF-1α in mouse granulosa cells. Cell Death Dis. 2017;8(8):e3001. https://doi.org/10.1038/cddis.2017.371. · DOI
  42. Jampol LM, Glassman AR, Sun J. Evaluation and care of patients with diabetic retinopathy. N Engl J Med. 2020;382(17):1629–37. https://doi.org/10.1056/NEJMra1909637. · DOI · Paper page
  43. Kumagai AK. Glucose transport in brain and retina: Implications in the management and complications of diabetes. Diabetes Metab Res Rev. 1999;15(4):261–73. https://doi.org/10.1002/(SICI)1520-7560(199907/08)15:4%3c261::AID-DMRR43%3e3.0.CO;2-Z. · DOI · Paper page
  44. Kumagai AK, Glasgow BJ, Pardridge WM. GLUT1 glucose transporter expression in the diabetic and nondiabetic human eye. Investig Ophthalmol Vis Sci. 1994;35(6):2887–94.
  45. Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in cells of the blood-retinal barrier in the rat. Investig Ophthalmol Vis Sci. 1992;33(2):377–83.
  46. Gospe SM, Baker SA, Arshavsky VY. Facilitative glucose transporter Glut1 is actively excluded from rod outer segments. J Cell Sci. 2010;123(Pt 21):3639–44. https://doi.org/10.1242/jcs.072389. · DOI
  47. Mantych GJ, Hageman GS, Devaskar SU. Characterization of glucose transporter isoforms in the adult and developing human eye. Endocrinology. 1993;133(2):600–7. https://doi.org/10.1210/endo.133.2.8344201. · doi:10.1210/endo.133.2.8344201
  48. Calado SM, Alves LS, Simão S, Silva GA. GLUT1 activity contributes to the impairment of PEDF secretion by the RPE. Mol Vis. 2016;22:761–70.
  49. Cloherty EK, Diamond DL, Heard KS, Carruthers A. Regulation of GLUT1-mediated sugar transport by an antiport/uniport switch mechanism. Biochemistry. 1996;35(40):13231–9. https://doi.org/10.1021/bi961208t. · doi:10.1021/bi961208t
  50. Adachi-Uehara N, Kato M, Nimura Y, et al. Up-regulation of genes for oxidative phosphorylation and protein turnover in diabetic mouse retina. Exp Eye Res. 2006;83(4):849–57. https://doi.org/10.1016/j.exer.2006.04.012. · DOI
  51. Nyengaard JR, Ido Y, Kilo C, Williamson JR. Interactions between diabetes and hypoxia retinopathy 2004 implications for diabetic retinopathy. Diabetes. 2004;53:2931–8. · DOI
  52. Imai H, Singh RSJ, Fort PE, Gardner TW. Neuroprotection for diabetic retinopathy. Dev Ophthalmol. 2009;44:56–68. https://doi.org/10.1159/000223946. · DOI
  53. Fernandes R, Suzuki K, Kumagai AK. Inner blood-retinal barrier GLUT1 in long-term diabetic rats: an immunogold electron microscopic study. Investig Ophthalmol Vis Sci. 2003;44(7):3150–4. https://doi.org/10.1167/iovs.02-1284. · DOI
  54. Fernandes R, Carvalho AL, Kumagai A, et al. Downregulation of retinal GLUT1 in diabetes by ubiquitinylation. Mol Vis. 2004;10:618–28.
  55. Badr GA, Tang J, Ismail-Beigi F, Kern TS. Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. Diabetes. 2000;49(6):1016–21. https://doi.org/10.2337/diabetes.49.6.1016. · DOI
  56. Kumagai AK, Vinores SA, Pardridge WM. Pathological upregulation of inner blood-retinal barrier Glut1 glucose transporter expression in diabetes mellitus. Brain Res. 1996;706(2):313–7. https://doi.org/10.1016/0006-8993(95)01335-0. · DOI
  57. Tang J, Mohr S, Du YP, Kern TS. Non-uniform distribution of lesions and biochemical abnormalities within the retina of diabetic humans. Curr Eye Res. 2003;27(1):7–13. https://doi.org/10.1076/ceyr.27.2.7.15455. · doi:10.1076/ceyr.27.2.7.15455
  58. Roy A, Hashmi S, Li Z, Dement AD, Cho KH, Kim JH. The glucose metabolite methylglyoxal inhibits expression of the glucose transporter genes by inactivating the cell surface glucose sensors Rgt2 and Snf3 in yeast. Mol Biol Cell. 2016;27(5):862–71. https://doi.org/10.1091/mbc.E15-11-0789. · doi:10.1091/mbc.e15-11-0789
  59. Stenina O. Regulation of vascular genes by glucose. Curr Pharm Des. 2005;11(18):2367–81. https://doi.org/10.2174/1381612054367283. · doi:10.2174/1381612054367283
  60. Stitt AW. AGEs and diabetic retinopathy. Investig Ophthalmol Vis Sci. 2010;51(10):4867–74. https://doi.org/10.1167/iovs.10-5881. · DOI · Paper page
  61. Kim D-I, Lim S-K, Park M-J, Han H-J, Kim G-Y, Park SH. The involvement of phosphatidylinositol 3-kinase /Akt signaling in high glucose-induced downregulation of GLUT-1 expression in ARPE cells. Life Sci. 2007;80(7):626–32. https://doi.org/10.1016/J.LFS.2006.10.026. · DOI
  62. Dehdashtian E, Mehrzadi S, Yousefi B, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018;193:20–33. https://doi.org/10.1016/j.lfs.2017.12.001. · DOI · Paper page
  63. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960–76. https://doi.org/10.1016/j.cell.2017.02.004. · DOI · Paper page
  64. Harwood FC, Klein Geltink RI, O’Hara BP, et al. ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Sci Adv. 2018. https://doi.org/10.1126/sciadv.aar3938. · DOI
  65. Buller CL, Heilig CW, Brosius FC. GLUT1 enhances mTOR activity independently of TSC2 and AMPK. Am J Physiol Ren Physiol. 2011;301(3):F588–96. https://doi.org/10.1152/ajprenal.00472.2010. · DOI
  66. Lu L, Seidel CP, Iwase T, et al. Suppression of GLUT1; A new strategy to prevent diabetic complications. J Cell Physiol. 2013;228(2):251–7. https://doi.org/10.1002/jcp.24133. · DOI
  67. Wei J, Jiang H, Gao H, Wang G. Blocking Mammalian target of rapamycin (mTOR) attenuates HIF-1α pathways engaged-vascular endothelial growth factor (VEGF) in diabetic retinopathy. Cell Physiol Biochem. 2016;40(6):1570–7. https://doi.org/10.1159/000453207. · DOI
  68. Zhang MH, Jiang JZ, Cai YL, Piao LH, Jin Z. Significance of dynamic changes in gastric smooth muscle cell apoptosis, PI3K-AKT-mTOR and AMPK-mTOR signaling in a rat model of diabetic gastroparesis. Mol Med Rep. 2017;16(2):1530–6. https://doi.org/10.3892/mmr.2017.6764. · DOI
  69. Shen L, You B, Gao H, Li B, Yu F, Pei F. Effects of phlorizin on vascular complications in diabetes db/db mice. Chin Med J Engl. 2012;125(20):3692–6. https://doi.org/10.3760/cma.j.issn.0366-6999.2012.20.017. · doi:10.3760/cma.j.issn.0366-6999.2012.20.017
  70. Zhang S, Li B, Li X, et al. Effects of phlorizin on diabetic retinopathy according to isobaric tags for relative and absolute quantification-based proteomics in db/db mice. Mol Vis. 2013;19:812–21.
  71. Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vis Res. 2017;139:7–14. https://doi.org/10.1016/j.visres.2017.04.003. · DOI · Paper page
  72. Fu D, Yu JY, Yang S, et al. Survival or death: a dual role for autophagy in stress-induced pericyte loss in diabetic retinopathy. Diabetologia. 2016;59(10):2251–61. https://doi.org/10.1007/s00125-016-4058-5. · DOI

Cited by

See all 44

Metadata

Authors
Madrakhimov, S. B., Yang, J. Y., Kim, J. H., Han, J. W., & Park, T. K.
Venue
Cell Communication and Signaling
Published
2021-02-26
Volume
19
Issue
1
ISSN
1478-811X
Cited by
44
References
12
Language
en
Licence
Funders
  • Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (2019R1A2C1005055)
  • Soonchunhyang University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mTOR-dependent dysregulation of autophagy contributes to the retinal ganglion cell loss in streptozotocin-induced diabetic retinopathy. https://app.cochat.ai/papers/10.1186/s12964-020-00698-4
The paper
Madrakhimov, S. B., Yang, J. Y., Kim, J. H., Han, J. W., & Park, T. K. (2021). mTOR-dependent dysregulation of autophagy contributes to the retinal ganglion cell loss in streptozotocin-induced diabetic retinopathy. Cell Communication and Signaling. https://doi.org/10.1186/s12964-020-00698-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.